Related Experiment Videos
Fluorodeoxyglucose PET/CT in Nonlymphoma Hematolymphoid Disorders
Akshay Bedmutha1, Michal Weiler-Sagie2, Leen Alkukhun1
1Department of Radiology & Imaging Sciences, Emory University, Atlanta, GA, USA.
PET Clinics
|August 10, 2026
Summary
Fluorodeoxyglucose-PET/CT is crucial for assessing multiple myeloma treatment response, with standardized criteria improving evaluation. Achieving complete metabolic response and minimal residual disease negativity offers the best prognosis.
Area of Science:
- Nuclear medicine imaging
- Hematology
- Oncology
Background:
- Fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) has a significant but variable role in nonlymphoma hematolymphoid disorders.
- Its application in multiple myeloma for treatment response assessment is well-established.
Purpose of the Study:
- To review the utility of FDG-PET/CT in nonlymphoma hematolymphoid disorders.
- To highlight its role in multiple myeloma response assessment and prognostic stratification.
Main Methods:
- Review of current literature and clinical guidelines.
- Focus on standardized interpretation criteria like Italian Myeloma criteria for PET Use/Deauville criteria.
- Analysis of prognostic value in landmark trials (e.g., CASSIOPEIA, FORTE).
Main Results:
- FDG-PET/CT is the preferred imaging modality for response assessment in multiple myeloma.
- Standardized criteria ensure reproducible evaluation and prognostic stratification.
- PET-based complete metabolic response and MRD negativity are strong prognostic indicators.
Conclusions:
- FDG-PET/CT is vital for managing multiple myeloma, offering robust prognostic insights.
- Limitations include challenges with nonavid disease and diffuse marrow infiltration.
- Combined FDG-PET/MR imaging shows emerging potential.